ARTICLE | Company News
Pfizer, Ab Initio deal
December 16, 2016 9:34 PM UTC
The companies partnered to use Ab Initio's platform to discover antibodies against an undisclosed target in the GPCR superfamily. Pfizer has exclusive, worldwide rights to develop and commercialize an...